Category: Accesswire

VANCOUVER, BC AND BREDA, THE NETHERLANDS / ACCESS Newswire / July 28, 2025 / Organto Foods Incorporated (TSX-V:OGO)(OTC:OGOFF) (“Organto” or the “Company”) (“Organto” or the “Company”) is pleased to announce the appointment of Mr. Javier Reyes de la Campa as Co-Chair of the Board of Directors, alongside Steve Bromley, effective immediately.

Javier Reyes de la Campa is a seasoned professional and entrepreneur with over 25 years of experience in investing and building companies. He has co-founded various firms across the finance, mining, agriculture and food sectors. More recently, his strategic leadership was instrumental in the strategic turnaround of Luca Mining Corporation, a producing company with assets in Mexico. Luca Mining Corporation was recently named to the 2025 Toronto Stock Exchange Venture 50™ list of top-performing companies. Mr. Reyes de la Campa was a founding director of Organto Foods and previously served on the Board of Directors from 2015 through 2020. An alumnus of Harvard Business School, Mr. Reyes de la Campa holds dual bachelor’s degrees in economics and business administration, as well as a master’s degree in finance from the Instituto Tecnológico Autónomo de México.

Steve Bromley, Chief Executive Officer and Co-Chair of Organto Foods, commented: “We are thrilled to welcome Javier as Co-Chair. His strategic insight, leadership experience, and international perspective will be invaluable as we continue to grow our platform and meet the increasing global demand for organic and responsibly sourced food products. Javier joins us at an optimal time, as the we are accelerating our growth and profitability as well as widening our product offering.”

Javier Reyes de la Campa, Co-Chairman, added: “I am honored and excited to join Organto’s Board of Directors at this exciting time for the Company. I admire the hard work of Steve and the entire team over the past eighteen months to reposition the Company for success. The Company’s mission to make healthy, organic foods more accessible and its dedication to sustainable business practices align closely with my own values. I look forward to working alongside the Board of Directors and management team to unlock the Company’s full potential and maximize shareholder value.”

Grant of Stock Options and Restricted Share Units

The Company also announces that it has granted 125,000 stock options to certain employees as per the terms of the Company’s Share Option Plan. The options were granted at an exercise price of $0.54 per share and have a term of five years. The options issued will vest 20% immediately and 20% on each anniversary thereafter. In addition, 1,000,000 restricted stock units were issued to certain directors of the Company as per the terms of the Company’s Restricted Share Unit Plan. The restricted share units have a term of 3 years and will vest one-third after one-year and one-third every six months thereafter.

ON BEHALF OF THE BOARD

Steve Bromley
Co-Chair and CEO

For more information, contact:
Investor Relations
John Rathwell, Senior Vice President, Corporate Development
647 629 0018
info@organto.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

ABOUT ORGANTO

Organto is a leading provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-lighter business model to serve a growing socially responsible and health-conscious consumers. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law, including without limitation, Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting the Company’s belief that Mr. Reyes de la Campa’s insight, leadership experience and international perspective will be invaluable as the Company grows its platform focused on meeting global demand for organic and responsibly sourced food products and the Company’s belief that Mr. Reyes de la Campa is joining at an optimal time as the Company is accelerating its growth and profitability and widening it product offering. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, without limitation, the assumption that Mr. Reyes de la Campa joining the Board of Directors as Co-Chair is a positive development for the Company. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in forward-looking statements in this news release include, among others, uncertainty regarding the regulatory risks; risks related to market volatility and economic conditions; risks related to unforeseen delays; and risks that necessary financing will be unavailable when needed. For further information on these and other risks and uncertainties that may affect the Company’s business, see the “Risks and Uncertainties” and “Forward-Looking Statements” sections of the Company’s annual and interim management’s discussion and analysis filings with the Canadian securities regulators, which are available under the Company’s profile at www.sedarplus.ca. Except as required by law, Organto does not assume any obligation to release publicly any revisions to forward-looking statements contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

TUALATIN, OR / ACCESS Newswire / July 28, 2025 / Monster Electrical is proud to announce its designation as a Master Distributor for Bussmann Edison fuses, significantly expanding its stocked inventory to better serve industrial and commercial customers nationwide.

With over 17,000 stocked SKUs and 125,000+ parts on hand, Monster Electrical now offers a full line of Bussmann Edison fuses, including Class CC, J, T, RK5, L, G, ECNR, ECSR, Midget, High Speed, and more. Whether it’s a standard order or an emergency replacement, customers can count on fast fulfillment, reliable delivery, and expert support 24/7/365.

“Our customers know us for ‘need-it-now’ solutions,” said Nick Palmer, President at Monster Electrical. “With this partnership, we’re doubling down on that promise-offering the right products when you need them, and the inventory depth to support your everyday stocking needs.”

Monster Electrical operates four strategically located distribution centers across the U.S. (Oregon, New Jersey, Illinois, and Texas), enabling same-day shipping and local pickup for time-critical orders. This expanded inventory supports a wide range of applications across a broad spectrum of the electrical industry.

To browse the full Bussmann Edison fuse catalog or to place an order, visit:

www.monsterelectrical.com/edisonfuses

Contact:
Monster Electrical
888.444.4333
sales@monsterelectrical.com

About Monster Electrical
Monster Electrical is a trusted B2B distributor serving the electrical industry with a focus on fuses and power distribution solutions. With more than 25 years of industry experience, Monster supports OEMs, MROs, and electrical distributors through a nationwide network of stocking locations and over 17,000 SKUs ready to ship. Known for its 24/7 emergency service model and deep product expertise, Monster Electrical offers the reliability, responsiveness, and inventory scale that today’s electrical professionals demand-whether for urgent replacements or ongoing stock replenishment.

SOURCE: Monster Electrical

View the original press release on ACCESS Newswire

Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth

LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2025 / Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificial intelligence. The new patents, including U.S. Application No. 18/058,732 for unbiased drug discovery predictions, expand Renovaro’s growing IP portfolio anchored by foundational patents U.S. No. 11,379,757 and recently awarded Application No. 18/058,752.

Key Value Drivers:

• Protected Competitive Moat in federated learning for healthcare, with continuation filings extending IP coverage by establishing broad protection around harmonizing biomedical data and applying frameworks for AI-powered prediction of both beneficial and harmful treatment effects.

• Enhances Partnership Opportunities by supporting high-value applications such as high-fidelity integration of heterogeneous datasets – including electronic health records (EHRs), imaging, genomics, and trial data – across distributed environments, directly enabling applications in drug discovery, clinical trials, rare disease research, and precision medicine.

• Breakthrough in Federated and Secure AI Learning: The newly issued patent covers a novel federated learning architecture that enables advanced AI model training across decentralized healthcare datasets – such as those held by hospitals, research institutions, or biopharma partners – without requiring the exchange of sensitive raw data. This innovation provides robust bidirectional security, protecting both the underlying data sources and the integrity of the resulting AI models, and positions the company at the forefront of privacy-preserving AI in healthcare

• Scalable and Reproducible AI Models designed for real-world deployment across heterogeneous data environments – an essential capability for future pharmaceutical and clinical partners.

• Robust IP Pipeline: Multiple continuation filings underway, providing sustained innovation and patent coverage over time.

Renovaro’s newly allowed patents include innovations titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” and “Methods, Systems, and Frameworks for Federated Learning While Ensuring Bi-Directional Data Security“. These methods address critical pain points in biomedical AI, such as data sparsity, source heterogeneity, and lack of model transferability – paving the way for reproducible AI models in precision medicine. These filings also deepen the company’s IP foundation by addressing key bottlenecks in the biomedical AI space – specifically, the integration of heterogeneous data such as EHRs, genomics, imaging, and clinical trial results into standardized pipelines capable of producing clinically relevant, reproducible insights.

These capabilities are particularly critical for applications in rare disease research, trial optimization, and therapeutic targeting – areas with strong unmet needs and have high-value partnership potential.

“Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine,” said David Weinstein, CEO, Renovaro.

With additional patents pending and a portfolio designed to scale with evolving interoperability standards and regulatory demands, Renovaro continues to solidify its position as a platform company with durable, defensible technology in a market estimated to reach over $20B by 2030.

About Renovaro (NASDAQ: RENB)

Renovaro is a forward-looking biotechnology company harnessing the power of artificial intelligence and data science to develop innovative therapies and diagnostics in oncology, infectious disease, and autoimmune disorders. By integrating cutting-edge machine learning with biomedical research, Renovaro aims to dramatically improve treatment outcomes and enable earlier disease detection.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our filings with the SEC for a discussion of these risks.

Contact:

investors@renovaro.com

www.renovarogroup.com

SOURCE: Renovaro Biosciences

View the original press release on ACCESS Newswire

Deliver intelligent data workflows that automatically schedule exports, trigger alerts, and deliver insights when and where they matter.

SAN FRANCISCO, CA / ACCESS Newswire / July 28, 2025 /
GoodData, the AI-native analytics platform, today launched


Intelligent Data Automation


: a powerful new framework designed for proactive insight delivery and operational responsiveness.

Intelligent Data Automation delivers seamless, scalable, and governed automation that drives reports, triggers alerts, and embeds analytics across operational workflows. Built for scale, governance, and developer control, GoodData’s automation layer accelerates decision-making while reducing alert fatigue and fragmented data workflows.

With Intelligent Data Automation, we’re closing the gap between data and action. Teams no longer have to wait for insights; they receive them automatically, in their preferred format, delivered to any endpoint, with the context they need to act fast. It’s automation designed for the AI era.

Ryan Dolley, VP of Product Strategy at GoodData

Intelligent Data Automation for Workflow-Embedded Analytics

With GoodData’s future-ready automation layer, users get:

• 
  Scheduled exports
  of dashboards and reports in PDF, XLSX, PNG, CSV, and more.

• 
  Event-based alerts
  triggered by threshold breaches, data changes, or predicted trends.

• 
  Multi-channel delivery
  via email, webhooks, cloud storage (e.g., S3), and embedding into applications.

• 
  Integrationwith popular tools
  like Slack, Salesforce, Jira, and more through flexible webhook and API connections, enabling custom workflows.

• 
  Context-aware, personalized insights
  tailored to user roles, filters, and permissions.

• 
  Full governance
  with tenant-level workspace isolation, role-based controls, and centralized monitoring.

This combination of no-code simplicity, real-time responsiveness, and user-aware personalization makes Intelligent Data Automation a powerful leap forward in operational analytics.

With GoodData, we’ve transformed our embedded analytics experience for our customers, giving them tailored, actionable insights into sales performance and customer engagement. Automation features like scheduled exports help ensure our users get the information they need, when they need it, which is a big upgrade to our analytics suite.

Outfield, Performance-based CRM

AI-Driven Automation Layer

GoodData is expanding its Intelligent Data Automation with a future-ready AI-driven automation layer. Designed to reduce noise and highlight what matters most, this development marks the beginning of a broader rollout of AI capabilities coming soon, offering an early look at more intelligent, proactive analytics.

Built-in from day one, Intelligent Data Automation is not a bolt-on or add-on – it’s part of GoodData’s core execution layer designed for modern SaaS vendors, embedded platforms, and multi-tenant environments. It delivers operational BI that works at scale, is developer-friendly, and drives faster, smarter decisions across thousands of users, dozens of systems, or entire customer bases.

To learn more about how Intelligent Data Automation can transform your data strategy, visit

gooddata.com

.

---

About GoodData

GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.

Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.

For more information, visit

GoodData’s website

and follow GoodData on

LinkedIn

,

YouTube

, and

Medium

.

GoodData Contact

press@gooddata.com

©2025, GoodData Corporation. All rights reserved. GoodData and the GoodData logo are registered trademarks of GoodData Corporation in the United States and other jurisdictions. Other names used herein may be trademarks of their respective owners.

SOURCE:
GoodData

View the original press release on ACCESS Newswire

CHARLOTTE, NC / ACCESS Newswire / July 28, 2025 / A sweeping federal court decision this month vacated the FTC’s “click-to-cancel” rule, keeping cumbersome contract cancellation practices alive throughout the wellness sector and beyond. While major wellness chains cling to rigid memberships, Zen Massage Franchising, Inc. is accelerating growth and amplifying its hassle-free, no-contract approach for consumers who want real choice. This growth initiative follows franchise industry veteran Keith Larson taking full ownership of the company.

“About 80 percent of Zen clients switched to us after dealing with brands that tie people into contracts or membership fees,” said CEO Larson, who brings deep expertise in franchise operations, marketing and media. “These bigger brands are trying to protect their so-called guaranteed revenue stream at their customers’ expense. They’re fighting against what their own clients want, but we give people freedom and flexibility in their wellness experiences. We believe you can succeed by respecting your customers-not trapping them.”

Zen Massage Franchising, Inc. operates eight massage and skincare centers across North Carolina, South Carolina, Nevada and Missouri, and under Larson’s direction, has secured new trademarks: “No Contracts. No Membership Fees. No Hassles!®” and “No Contracts. No Membership Fees. Just Aaaah!®”.

With an eye on system-wide growth, the company is ramping up its franchise campaign offering low startup fees, streamlined operations, robust marketing resources and comprehensive training-all centralized from its Cornelius, N.C.-based headquarters and training center.

The FTC’s scrapped rule, originally slated to take effect July 14, would have required companies to make cancellation as easy as sign-up. Its abrupt halt, blocked on procedural grounds, leaves consumers tangled in a patchwork of state policies and frustrating fine print.

“Consumers hate contracts and are exhausted by cancellation headaches, whether it’s cellphone plans, streaming services or massage memberships,” Larson said. “They will make different choices once they’re given the chance.”

With no word yet from the FTC on the rule’s future, Zen Massage Franchising Inc. stays a decisive step ahead, offering the customer flexibility that the rest of the industry won’t.

Larson’s history with Zen Massage spans more than a decade. He first joined in 2013 through a system rebranding initiative led by his advertising agency, became a minority investor in 2018, a franchisee in 2019, was named CEO in 2021-culminating in his full acquisition of the company in late spring 2025. Larson spent 13 years with McDonald’s Corp., rising to regional director of franchised operations, then served as senior vice president at Moroch, one of McDonald’s top ad agencies.

About Zen Massage Franchising, Inc.

Zen Massage Franchising, Inc. offers a competitive advantage for consumers and franchisees in the growing wellness sector. For consumers, there are no binding contracts or membership fees. Instead, the company provides everyday value pricing and a straightforward experience. Franchisees benefit from lower startup fees, efficient center operations, robust support, and significant opportunities for growth. The company supports franchisees with comprehensive training, operational guidance, and marketing resources from its Cornelius, N.C.-based headquarters and training center.

Franchise offerings are only made through the Zen Massage Franchise Disclosure Document (FDD) and process. For franchise information, contact Larson at klarson@zenmassageusa.com or (704) 947-9162, or visit zenmassageusa.com/franchise-information/.

SOURCE: Zen Massage Franchising, Inc.

View the original press release on ACCESS Newswire

Alpha Capital Anstalt, Brenmiller Energy’s largest shareholder and long-standing investor, reinforces its strong commitment to the Company’s long-term strategy

The Company will receive $1.2 million in an initial closing and an additional $3.8 million subject to certain conditions

Alpha Capital Anstalt has Additional Investment Rights for up to $20 million

DIMONA, ISRAEL / ACCESS Newswire / July 28, 2025 / Brenmiller Energy Ltd. (“Brenmiller”, “Brenmiller Energy” or the “Company”) (Nasdaq:BNRG), a leading global provider of thermal energy storage (“TES”) solutions for industrial and utility customers, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Alpha Capital Anstalt (“Alpha”). Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to Alpha, subject to certain conditions, up to an aggregate of $25 million in securities across multiple tranches, consisting of preferred shares, pre-funded warrants, and ordinary warrants.

At the initial closing, expected to take place on or about July 28, 2025, for a subscription amount of $1.2 million the Company will issue (i) pre-funded warrants to purchase 631,579 ordinary shares at an exercise price of $0.00001 per share (the “Pre-Funded Warrants”) and (ii) ordinary warrants to purchase 631,579 ordinary shares at an exercise price of $2.09 per share (the “Ordinary Warrants”). The Pre-Funded Warrants will be exercisable upon issuance and will expire when exercised in full. The Ordinary Warrants will be exercisable upon issuance and expire five years from the initial exercise date. The exercise of the Pre-Funded Warrants and Ordinary Warrants are subject to certain beneficial ownership limitations contained therein.

Subject to receipt of certain shareholder approvals, the Company will issue preferred shares with a stated value of $1,000 per share, or the Preferred Shares, in exchange for an additional $3.8 million investment (the “Equity Closing”). Each Preferred Share is convertible into ordinary shares at a fixed conversion price of $2.288 per share. At the Equity Closing, the Company will also issue accompanying ordinary warrants, with an exercise price of $2.40 per share (the “Additional Ordinary Warrants”), equal to 100% of the shares underlying the Preferred Shares, which will be exercisable upon issuance and will expire five years from the initial exercise date.

The proceeds from the financing will be used for general corporate purposes, working capital, and execution of Brenmiller’s commercial TES projects across Europe, the U.S., and the Middle East.

Under the terms of the Securities Purchase Agreement, subject to certain conditions and as long as any Preferred Shares or Additional Ordinary Warrants are outstanding, Alpha also has the right to purchase additional preferred shares and warrants from the Company up to an additional $20 million (“Subsequent Financing”).

The Securities Purchase Agreement also provides for certain additional fundings by Alpha after the Equity Closing which can come in the form of warrant exercises, Subsequent Financing or other financing arranged by Alpha (the “Additional Funding”), subject to certain conditions, up to $15 million, over a two year period beginning after the Equity Closing. Assuming full exercise of all warrants, the overall financing from Alpha may reach $50 million.

Approval of the Company’s shareholders is required for the Equity Closing under the Company’s constitutive documents and applicable law allowing for, among other things, the issuance of the Preferred Shares, including all the underlying shares, and for the Company to issue in excess of 24.99% of the Company’s ordinary shares outstanding on the Equity Closing (including any existing ordinary shares held by Alpha).

In addition, on July 25, 2025, the Company entered into two separate Registration Rights Agreements with Alpha pertaining to (i) the resale of the ordinary shares issuable upon exercise of the warrants issued at the Pre-Funded Warrants Closing and (ii) the resale of the ordinary shares issuable upon conversion of the Preferred Shares and exercise of the Additional Ordinary Warrants to be issued at the Equity Closing. The Company agreed to file these registration statements with the U.S. Securities and Exchange Commission and maintain their effectiveness within specified timeframes.

The securities are being offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities Act, and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, once issued, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About bGen™

bGen™ ZERO is Brenmiller’s TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME’s Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards.

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company uses forward-looking statements when it discusses: the Company’s ability to raise up to $20 million in Subsequent Financing; the $3.8 million in Preferred Shares and Additional Warrants to be issued upon receipt of shareholder approval; Alpha Capital Anstalt’s providing additional funding up to $15 million over a two year period after the Equity Closing; Alpha Capital Anstalt’s commitment to the Company’s long-term strategy; the use of proceeds from the equity financings described in this press release; and the overall financing which may reach $50 million assuming full exercise of all warrants, which may never be exercised. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire

TORONTO, ONTARIO / ACCESS Newswire / July 28, 2025 / Consumer Choice Award is pleased to announce the 2025 award recipients in the Toronto Central region. These businesses have been meticulously selected through independent market research, reflecting their commitment to excellence and unparalleled service in their city. Consumer Choice Award celebrates those who have consistently set the benchmark for quality and customer satisfaction. Congratulations to the 2025 Toronto Central Consumer Choice Award Winners.

TORONTO CENTRAL AWARD RECIPIENTS

Abrams Towing Towing Services www.abrams.ca		Acme Lock & Key Locksmith www.KeysCut.ca
Affordable Burials & Cremations Funeral Services www.affordableburialsandcremations.ca		AMB Driving School Driving Schools www.ambdriving.com
Aqua-Tots Swim Schools North York Swimming Lessons www.aqua-tots.com/north-york		AutoLoans.ca Automotive Financing & Leasing www.AutoLoans.ca
BeHot Yoga Toronto Yoga Studio www.behotyogatoronto.com		Bochner Eye Institute Ophthalmology www.bochner.com
Cloverhill Gardening Landscaping Landscape Contractors www.cloverhillgardening.com		Condor Security Inc. Security Guard Services www.condorsecurity.ca
Del Grande Homes Swimming Pool Contractors Dealers Designers www.delgrandehomes.com		Drain King Plumbers Toronto Drainage & Sewer Services www.drainkingplumbers.ca
E.W. Smith Roofing Roofing www.ewsmithroofing.com		Elite Martial Arts Martial Arts www.emakravmaga.ca
Excelsior Integrative Massage Therapy and Wellness Massage Therapy www.excelsiorintegrative.com		Eyes On Sheppard Clinic Opticians / Optometrists www.eyesonsheppard.com
FCP Dermatology Dermatologist www.fcpdermatology.com		Fingerprinter Identification Services & Digital Fingerprinting www.thefingerprinter.com
Friendly Truck Driving School Driving Schools – Truck www.friendlydrive.com		Gala Travel Travel Agencies www.galatravels.com
Gardenzilla Lawn & Garden Sod Supply and Services www.gardenzilla.ca		Genesis Land Surveying Inc. Surveyor Services www.genesislandsurvey.com
Heart Payroll Payroll Services www.heartpayroll.com		Heaven Can Wait First Aid Health & Safety Training www.heavencanwait.biz
Hinton Access Solutions Scaffolding www.hintonscaffold.com		Hometurf Lawn Care Lawn Maintenance www.hometurf.ca
HouseMaster Home Inspections Serving Toronto Home Inspection www.housemastertoronto.com		Imperium Barbershop Barber www.imperiumbarber.com
Kings Gate Luxury Homes Home Builders www.kingsgateluxuryhomes.com		KVM Limousine Services Limousine Services www.kvmlimo.com
Leaside Orthodontic Centre Orthodontists www.leasideorthodonticcentre.ca		Master Mechanic Automobile Repair www.mastermechanic.ca
Maydone Appliance Repair Residential and Commercial Appliance Repair www.maydone.com		Notarizers Notary Public www.notarizers.ca
Odd Job Handyman Services Handyman Services www.oddjob.ca		Ontario Business Central Inc Business Registration Services in Canada www.ontariobusinesscentral.ca
Pestend Pest Control Pest Control www.pestend.ca		Polaron Solartech Corp Solar Energy Systems www.polaronsolar.com
Priority Plumbing Plumbing Contractor www.priorityplumbing.ca		Pure Rejuvenation Anti Aging & Laser Clinic Cosmetic Procedures www.purerejuvenation.ca
Real Estate Lawyer Toronto – LD Law LLP Lawyer – Real Estate Law www.ldlaw.ca		Riders Plus Insurance Insurance – Home and Auto www.ridersplus.com
Rosedale Wellness Centre Chiropractors www.rosedalewellness.com		Royal Lepage Terrequity Realty Real Estate Residential www.terrequity.com
Safetech Alarm Systems Alarm Systems www.safetechalarms.com		Scottify Productions DJ Services www.scottify.ca
Singers Edge & Toronto Arts Academy School – Music www.singersedge.com		StyleBite Staging Home Staging Services www.stylebitestaging.com
Sure Hair Transplants Hair Restoration www.surehair.com		Teachers On Call Tutoring www.teachersoncall.ca
Tesla Electric Electrical Contractor www.teslaelectric.ca		The Parking Lot Guys Inc. Paving Contractor www.theparkinglotguys.ca
Tony & Sons Cranes Cranes www.tonyandsonscranes.com		Toronto Comfort Zone Fireplace Sales & Service www.torontocomfortzone.com
Undo It MacBook Repair / Computer Services www.undoit.ca		Walkrite Foot Clinic Podiatrists / Foot Clinic www.walkritefootclinic.com
Woodfield Canada Inc – Toronto Work Vehicle Equipment www.woodfieldcanada.ca		WOW 1 DAY PAINTING Painting Contractor www.wow1day.com
WRAPS IN 6IX Automobile Wrapping www.wrapsin6ix.ca

Learn more about 2025 Toronto Central Consumer Choice Award Winners HERE.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Conversation will feature visionary crypto leaders  Ryan Zurrer of Dialectic, Robert Leshner of Superstate, and Rhydon Lee of Goff Capital

FRISCO, TEXAS / ACCESS Newswire / July 28, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME) provides a link for its previously announced livestream on July 29, 2025 at 12:00 p.m. ET. The livestream will feature Justin Kenna, CEO of GameSquare, alongside its newest advisors and investors, a collective of the most forward-thinking leaders in decentralized finance:. Ryan Zurrer, Founder of Dialectic AG, Robert Leshner, CEO of Superstate, and Rhydon Lee of Goff Capital.

Tomorrow’s discussion comes at a pivotal moment for GameSquare, as the company accelerates its push into crypto with a series of bold, strategic moves. In just a matter of weeks, GameSquare has partnered with Dialectic, announced plans to scale its ETH treasury to $250 million, and acquired the Cowboy Ape, one of the most iconic CryptoPunks in a headline-grabbing deal that underscored the company’s belief in the long-term cultural and financial value of digital assets. These decisions aren’t isolated plays; they reflect GameSquare’s broader commitment to bringing digital-native fluency to public markets, with an approach rooted in culture, credibility, and strategic execution.Kenna, Zurrer, Leshner and Lee will provide a transparent, front-row look at the Company’s strategy, unpack the thinking behind these latest moves and explain what sets GameSquare apart from other public companies deploying ETH treasury strategies.

One of the key messages that the team will relay in tomorrow’s livestream is that GameSquare isn’t just another ETH treasury company. Since its inception in 2020, it’s created a core business that was built by connecting mainstream players to digital native audiences and educating the traditional marketplace on internet culture. A true market leading digital company, GameSquare provides services across advanced technology and data solutions, internet-first creative and production agencies, and the development and execution of authentic content and live experiences that uniquely serve internet-native audiences. The reason GameSquare has progressed their financial strategy into crypto is because it is a natural expansion of the Company’s current ecosystem that is truly authentic.

The livestream can be accessed at https://event.choruscall.com/mediaframe/webcast.html?webcastid=1zuS67xu and is also available at https://investors.gamesquare.com/events-and-presentations/events/default.aspx.

About GameSquare Holdings, Inc.

GameSquare (NASDAQ:GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. Complementing our operating strategy, GameSquare operates a blockchain-native Ethereum treasury management program designed to generate onchain yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.

To learn more, visit www.gamesquare.com.

Forward-Looking Statements:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company’s future performance, revenue, growth and profitability; and the Company’s ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company’s ability to grow its business and being able to execute on its business plans, the success of Company’s vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company’s ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company’s portfolio across entertainment and media platforms, dependence on the Company’s key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company’s most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

GameSquare Corporate Contact
Lou Schwartz, President
Phone: (216) 464-6400
Email: ir@gamesquare.com

GameSquare Investor Relations
Andrew Berger
Phone: (216) 464-6400
Email: ir@gamesquare.com

GameSquare Media Relations
Chelsey Northern / The Untold
Phone: (254) 855-4028
Email: pr@gamesquare.com

SOURCE: GameSquare Holdings, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presentation on mRNA-4359, Moderna’s investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, as well as two poster presentations on intismeran autogene (V940/mRNA-4157). Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.

The details of the presentations are as follows:

• Presentation #1515MO: Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma

  Mini Oral Presentation: October 17, 2025, 2:00 – 3:30 PM CET

  Location: Nuremberg Auditorium – Hall 5.2

  Presenter: David J. Pinato

• Presentation #3135eTiP: INTerpath-011: Phase 2 study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC)​

  Presenter: Petros Grivas

• Presentation #1684TiP: Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: the phase 2 INTerpath-012 study

  Presenter: Paolo A. Ascierto

Moderna Investor Event

Moderna will host an analyst event while at ESMO. Details of the event to follow.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer’s and other neurodegenerative diseases.

ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer’s Association International Conference 2025 (AAIC^®) in Toronto.

This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).

The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer’s disease.

No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C_max) and area under the plasma concentration-time curve (AUC_0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%).

Abidin Gülmüş, Chairman of GEN, stated:
“We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer’s disease.”

Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:
“With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer’s disease.”

About SUL-238
SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell’s “powerhouse.” It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications.

About GEN:
Founded in 1998, GEN is Türkiye’s leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments.

About Sulfateq:
Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.

For more information:
www.genilac.com.tr
www.sulfateqbv.com

SOURCE: GEN İlaç ve Sağlık Ürünleri A.Ş.

View the original press release on ACCESS Newswire